Swedish Orphan Biovitrum (SOBI) M&A Announcement summary

Deal rationale and strategic fit

• Acquisition adds AR882/pozdeutinurad, a next-generation URAT1 inhibitor, expanding the gout pipeline and addressing a large, underserved US patient population with over 200,000 uncontrolled cases.

• Complements existing assets, enabling a competitive franchise across the gout treatment spectrum and supporting long-term growth.

• Elevates capabilities through integration of a highly experienced team and continues a strategy of sourcing first- and best-in-class molecules.

• Expands the pipeline with a late-stage, de-risked program and strengthens position in the gout market.

• Expected to accelerate growth through the mid-2030s and beyond.

Financial terms and conditions

• Upfront payment of $950 million in cash, funded mainly through available liquidity and new credit facilities.

• Up to $550 million in additional clinical, regulatory, and sales milestones, mostly sales-related.

• Leverage expected to rise to around 2x at closing, then decrease through 2026 cash flows.

• Transaction expected to close in H1 2026, subject to customary closing conditions.

Synergies and expected cost savings

• Commercial and medical synergies anticipated with existing gout assets; field force will be augmented, not duplicated.

• Acquisition expected to be highly accretive to net sales, earnings, and margin trajectory in the mid- to long-term, fueling growth into the 2030s and early 2040s.

• No reduction in investment for NASP; the new asset builds on the established core and expands reach.